All Stories

  1. Exploring HMMR as a therapeutic frontier in breast cancer treatment, its interaction with various cell cycle genes, and targeting its overexpression through specific inhibitors
  2. Transcription factors-golden keys to modulate the plant metabolism to develop salinity tolerance
  3. Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology
  4. Targeting p53 misfolding conundrum by stabilizing agents and their analogs in breast cancer therapy: a comprehensive computational analysis
  5. Decoding the molecular mechanism of stypoldione against breast cancer through network pharmacology and experimental validation
  6. Network pharmacology and experimental validation for deciphering the action mechanism of Fritillaria cirrhosa D. Don constituents in suppressing breast carcinoma
  7. A comprehensive analysis of notch signaling genes in breast cancer: Expression pattern and prognostic significance
  8. Mechanistic elucidation of Juglanthraquinone C targeting breast Cancer: A network Pharmacology-based investigation
  9. A network pharmacology-based investigation of brugine reveals its multi-target molecular mechanism against Breast Cancer
  10. Role of diacerein on steroidogenesis and folliculogenesis related genes in ovary of letrozole-induced PCOS mice
  11. Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis
  12. Antituberculosis Propensity of Synthetic Biscoumarin Derivatives: An In Silico and In Vitro Approach
  13. Chlorogenic Acid Restores Ovarian Functions in Mice with Letrozole-Induced Polycystic Ovarian Syndrome Via Modulation of Adiponectin Receptor
  14. Synthesis and Biological Evaluation of Novel Uracil Derivatives as Thymidylate Synthase Inhibitors
  15. Breast Tumor Microenvironment and CDKs
  16. CCL2–CCR2 Signaling Axis in Cancer
  17. CCL5/CCR5 Axis in Cancer
  18. CDK Dysregulation in Breast Cancer: A Bioinformatics Analysis
  19. CDK1 Dysregulation in Breast Cancer
  20. CDKs in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
  21. CDk Inhibitor for Treatment of Breast Cancer
  22. Cdk4/Cdk6 Dysregulation in Estrogen-Positive Receptor Breast Cancers
  23. Cell Cycle Dysregulation in Breast Cancer
  24. Cell Cycle and Cancer
  25. Chemokine and Cytokine Network in Angiogenesis
  26. Chemokine and Cytokine Networks in Tumor Microenvironment
  27. Chemokines in Cancer Therapy
  28. Current Treatment Approaches to Breast Cancer
  29. Cytokines and Chemokines in Tumor Growth and Progression
  30. Different Cyclins and Their Significance in Breast Cancer
  31. Implications of Chemokine Heterogenicity in Cancer Metastasis
  32. Introduction to Breast Cancer
  33. Introduction to Cell Cycle and Its Regulators
  34. Introduction to Cytokine and Chemokine Networks
  35. Novel CDK Inhibitors in Breast Cancer
  36. Prognostic and Diagnostic Significance of Chemokines and Cytokines in Cancer
  37. Response of Therapy in Cell-Cycle Regulatory Genes in Breast Cancer
  38. Role of the CXCL8–CXCR1/2 Axis in Cancer and Inflammatory Diseases
  39. Targeting CDKs with Other Chemotherapeutic Drugs: A Combinatorial Approach
  40. The Interleukin-8 Pathway in Cancer
  41. The Role of Interleukin (IL)-6/IL-6 Receptor Axis in Cancer
  42. Therapeutic Implications of CDKs in Breast Cancer
  43. Therapeutic Implications of Cytokines and Chemokines Network in Cancer
  44. Evaluation of the In Vitro Antimicrobial Activities of Delphinium roylei: An Insight from Molecular Docking and MD-Simulation Studies
  45. Strategies Employed to Evade the Host Immune Response and the Mechanism of Drug Resistance in Mycobacterium tuberculosis: In Search of Finding New Targets
  46. Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications
  47. Identification and analysis of dysregulated fatty acid metabolism genes in breast cancer subtypes
  48. Cryptolepine Targets TOP2A and Inhibits Tumor Cell Proliferation in Breast Cancer Cells -An In vitroandIn silicoStudy
  49. Antimicrobial resistance: new insights and therapeutic implications
  50. Synthesis and Biological Evaluation of Novel Uracil Derivatives as Thymidylate Synthase Inhibitors
  51. Natural products and their semi-synthetic derivatives against antimicrobial-resistant human pathogenic bacteria and fungi
  52. Manipulation and exploitation of host immune system by pathogenicMycobacterium tuberculosisfor its advantage
  53. Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC-0941
  54. Expression Pattern and Prognostic Significance of Chemokines in Breast cancer: An Integrated Bioinformatics Analysis
  55. Expression patterns and therapeutic implications of CDK4 across multiple carcinomas: a molecular docking and MD simulation study
  56. Molecular docking analysis and evaluation of the antimicrobial properties of the constituents of Geranium wallichianum D. Don ex Sweet from Kashmir Himalaya
  57. Quinidine drug resistance transporter knockout Candida cells modulate glucose transporter expression and accumulate metabolites leading to enhanced azole drug resistance
  58. Expression pattern and prognostic significance of baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) in breast cancer: A comprehensive analysis
  59. A Novel Prognostic Biomarker with Potential of High Diagnostic Accuracy in Pulmonary Tuberculosis: An in silico Study
  60. Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors
  61. In vitro and in silico evaluation of antimicrobial properties of Delphinium cashmerianum L., a medicinal herb growing in Kashmir, India
  62. Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing
  63. Natural Therapeutics in Aid of Treating Alzheimer’s Disease: A Green Gateway Toward Ending Quest for Treating Neurological Disorders
  64. Expression pattern and prognostic significance of CDKs in breast cancer: An integrated bioinformatic study
  65. Metabolite fingerprinting of phytoconstituents from Fritillaria cirrhosa D. Don and molecular docking analysis of bioactive peonidin with microbial drug target proteins
  66. Metformin treatment ameliorates endocrine-metabolic disturbances in letrozole-induced PCOS mice model by modulating adiponectin status
  67. Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implications
  68. miRNAs as novel immunoregulators in cancer
  69. Elucidating genetic variability pertaining to flowering, maturity and morphological characters among various apple (Malus ✕ domestica Borkh.) cultivars
  70. Role of immunogenetics polymorphisms in infectious diseases
  71. Breast cancer stem cells and their role in tumor microenvironment
  72. Introduction to various types of cancers
  73. Role of Tumor Microenvironment in Breast Cancer and Targeted Therapies
  74. Role of Tumor-associated neutrophils in the breast tumor microenvironment
  75. Role of cancer-associated fibroblasts in tumor microenvironment
  76. Role of mesenchymal stem cells in tumor microenvironment
  77. Role of regulatory T cells in cancer
  78. Role of tumor-associated macrophages in the breast tumor microenvironment
  79. Targeting tumor microenvironment for breast cancer treatment
  80. The extracellular matrix in breast cancer
  81. The tumor microenvironment
  82. Conventional adjuvant chemotherapy in combination with surgery, radiotherapy, and other specific targets
  83. Current therapeutics and treatment options in TNBC
  84. Different drug delivery approaches in combinational therapy in TNBC
  85. Novel biomarkers in triple-negative breast cancer - role and perspective
  86. Role of immune system in TNBC
  87. Targeting biologically specific molecules in triple negative breast cancer (TNBC)
  88. The interplay of immunotherapy, chemotherapy, and targeted therapy in tripple negative breast cancer (TNBC)
  89. Triple-negative breast cancer - an aggressive subtype of breast cancer
  90. Combating human bacterial infections
  91. Combating human fungal infections
  92. Combinatorial approach to combat drug resistance in human pathogenic bacteria
  93. Combinatorial approach to combat drug resistance in human pathogenic fungi
  94. Evolution of antimicrobial drug resistance in human pathogenic bacteria
  95. Evolution of antimicrobial drug resistance in human pathogenic fungi
  96. Human pathogenic microbes (bacterial and fungal) and associated diseases
  97. Recent trends in the development of bacterial and fungal vaccines
  98. Significance of immunotherapy for human bacterial diseases and antibacterial drug discovery
  99. Significance of immunotherapy for human fungal diseases and antifungal drug discovery
  100. Correction: Reprogramming of Glucose Metabolism by Zerumbone Suppresses Hepatocarcinogenesis
  101. Nano-Drug Delivery Systems: Possible End to the Rising Threats of Tuberculosis
  102. An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer
  103. Antioxidants (Natural and Synthetic) Screening Assays: An Overview
  104. Antioxidants in Cancer Prevention and Combination Therapy
  105. The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities
  106. Novel Strategies to Combat the Emerging Drug Resistance in Human Pathogenic Microbes
  107. Recent Advances in Chemotherapeutic Implications of Deguelin: A Plant-Derived Retinoid
  108. Comparative Study on Phytochemical Profile and Antioxidant Activity of an Epiphyte, Viscum album L. (White Berry Mistletoe), Derived from Different Host Trees
  109. Glucose - The X factor for the survival of human fungal pathogens and disease progression in the host
  110. Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives
  111. Correction: Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy
  112. Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy
  113. Tumor microenvironment promotes breast cancer chemoresistance
  114. Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy
  115. Combination Therapies and their Effectiveness in Breast Cancer Treatment
  116. Chemotherapy in Combination with Surgery and Radiotherapy in Breast Cancer
  117. Different Drug Delivery Approaches for Breast Cancer
  118. Immunotherapy and Chemotherapy in Breast Cancer
  119. Therapeutic Landscape of Metaplastic Breast Cancer
  120. An Introduction to Breast Cancer
  121. Combination Therapy with Phytochemicals in Breast Cancer
  122. Nanomedicine in Human Health Therapeutics and Drug Delivery
  123. Novel Biomarkers in Breast Cancer
  124. Therapeutic Options for Breast Cancer
  125. Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma
  126. Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer
  127. Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis
  128. Nanobodies: The “Magic Bullets” in therapeutics, drug delivery and diagnostics
  129. Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma
  130. Recent Advances in Head and Neck Tumor Microenvironment–Based Therapy
  131. Recent Advances in Metabolites from Medicinal Plants in Cancer Prevention and Treatment
  132. Double-crosser of the Immune System: Macrophages in Tumor Progression and Metastasis
  133. Abstract 3470: Ibrutinib and sorafenib synergistically inhibit HCC growth in preclinical models
  134. Jasmonic Acid Improves Growth Performance of Soybean Under Nickel Toxicity By Regulating Nickel Uptake, Redox Balance, and Oxidative Stress Metabolism
  135. Jasmonic acid ameliorates alkaline stress by improving growth performance, ascorbate glutathione cycle and glyoxylase system in maize seedlings
  136. In vitro digestion, physicochemical and morphological properties of low glycemic index rice flour prepared through enzymatic hydrolysis
  137. Study on the quality control analysis of antiepileptic drugs using high-performance liquid chromatography
  138. Abstract 141: CD44 positive and sorafenib resistant hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128
  139. Abstract 2521: Inhibition of metabolic reprogramming by zerumbone alters the tumorigenic potential of hepatocellular cancer
  140. Jasmonic Acid Modulates the Physio-Biochemical Attributes, Antioxidant Enzyme Activity, and Gene Expression in Glycine max under Nickel Toxicity
  141. BAD, a Proapoptotic Protein, Escapes ERK/RSK Phosphorylation in Deguelin and siRNA-Treated HeLa Cells
  142. Immunomodulation of Inflammatory Markers in Activated Macrophages by Leaf Extracts of Gingko Biloba
  143. Modulatory role of jasmonic acid on photosynthetic pigments, antioxidants and stress markers of Glycine max L. under nickel stress
  144. Abstract 3363: RAGE/S100A7/Stat3-axis enhances breast cancer growth and metastasis via modulating tumor microenvironment
  145. 123I-FP-CIT SPECT imaging in early diagnosis of dementia in patients with and without a vascular component
  146. Concept of Reverse Costimulation and Its Role in Diseases
  147. Costimulation Immunotherapy in Allergies and Asthma
  148. Costimulation Immunotherapy in Infectious Diseases
  149. Costimulation in Lymphomas and Cancers
  150. Developing Costimulatory Molecules for Immunotherapy of Diseases
  151. Introduction to Costimulation and Costimulatory Molecules
  152. T-Cell Costimulation and Its Applications in Diseases
  153. 2014 Canadian Stroke Congress Abstracts
  154. Abstract 1166: CXCR7-mediated signaling axis regulates breast cancer growth and metastasis by modulating tumor microenvironment
  155. Inflammatory Mechanisms as Potential Therapeutic Targets in Stroke
  156. Tuberculosis Timebomb a Global Emergency : Need for Alternative Vaccines
  157. Regulatory mechanisms of intestinal folate uptake in a rat model of folate oversupplementation
  158. Signaling through CD80: an approach for treating lymphomas
  159. Influence of CD80 and CD86 Co-Stimulation in the Modulation of the Activation of Antigen Presenting Cells
  160. CASE REPORT: Haemosuccus pancreaticus: A clinical challenge